DEPARTMENT OF HEALTH & HUMAN SERVICES



National Institutes of Health National Institute on Drug Abuse Intramural Research Program 5500 Nathan Shock Drive Baltimore, MD 21224

April 19, 2005

U.S. Nuclear Regulatory Commission, Region I Nuclear Materials Safety Section B 475 Allendale Rd. King of Prussia, PA 19406

19-09760.02 03031714

Attn: Ms. Marjorie McLaughlin Health Physicist

STATEMENT OF INTENT

As Director of the Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, I exercise express authority and responsibility to request from the National Institutes of Health funds for decommissioning activities associated with operations authorized by U.S. Nuclear Regulatory Commission Material License No. 19-09760-02. This authority devolves from the U.S. Department of Health and Human Services, and inheres in my position. Within this authority, I intend to request that funds be made available when and if necessary in the amount of \$1,125 K to decommission Building C, located at 5500 Nathan Shock Drive, Baltimore, MD 21224, actual cost of which is estimated at \$1,000. I intend to request and obtain these funds sufficiently in advance of decommissioning to prevent delay of required decommissioning activities.

NONNEGOTIABLE

Barry J. Hoffer, M.D., Ph.D. Director Intramural Research Program National Institute on Drug Abuse, NIH

s/a assurance.nrc.4-2005



CERTIFICATION OF FINANCIAL ASSURANCE

Principal: National Institute on Drug Abuse Intramural Research Program National Institutes of Health, DHHS 5500 Nathan Shock Dr. Baltimore, MD 21224

License #: 19-09760-02

Facility

Addresses: 5500 Nathan Shock Dr. Baltimore, MD 21224

> 333 Cassell Dr. Baltimore, MD 21224

5510 Nathan Shock Dr. Baltimore, MD 21224

Issued to: U.S. Nuclear Regulatory Commission

I certify that the National Institute on Drug Abuse Intramural Research Program is licensed to possess the types of unsealed byproduct material, and sealed sources or foils, with half-life greater than 120 days, permitted by the above-captioned Type B broad-scope license under 10 CFR Part 30.

I further certify that financial assurance in the amount of \$1,125 K has been obtained for the purpose of decommissioning as prescribed by 10 CFR Part 30.

Barry J. Hoffer, M.D., Ph.D. Director Intramural Research Program National Institute on Drug Abuse, NIH

This is to acknowledge	the receipt of your letter/application dated
includes an administrat	and to Inform you that the initial processing which tive review has been performed.
technical reviewer.	ASSUIGNCC $19 - 09740-02$ inistrative omissions. Your application was assigned to a Please note that the technical review may identify additional e additional information.
Please provide to th	is office within 30 days of your receipt of this card
	· · · · · · · · · · · · · · · · · · ·
	as been forwarded to our License Fee & Accounts Receivable ct you separately if there is a fee issue involved.
Branch, who will contac Your action has been a When calling to inquire	
Branch, who will contac Your action has been a When calling to inquire	ct you separately if there is a fee issue involved. Issigned Mail Control Number <u>136917</u> . about this action, please refer to this control number.

.

. . . .

.

	: (FOR LFMS USE)
	: INFORMATION FROM LTS
BETWEEN:	
	:
License Fee Management Branch, ARM	: Program Code: 03611
and	: Status Code: 0
Regional Licensing Sections	: Fee Category: EX 3L
	: Exp. Date: 20101031
	: Fee Comments:
	: Decom Fin Assur Reqd: Y

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
Applicant/Licensee: HEALTH & HUMAN SERVICES, DEPT. OF
Received Date: 20050422
Docket No: 3031714
Control No.: 136917
License No.: 19-09760-02
Action Type: Fin. Assurance

- 2. FEE ATTACHED Amount: Check No.:
- 3. COMMENTS

Signed Date 412212005

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for: Amendment _______ Renewal ______ License ______

3. OTHER

Signed Date
